Clinical Trials Logo

Clinical Trial Summary

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04150497
Study type Interventional
Source Cellectis S.A.
Contact Cellectis Central Contact
Phone +1 (347) 752-4044
Email clinicaltrials@cellectis.com
Status Recruiting
Phase Phase 1
Start date October 14, 2019
Completion date January 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03671460 - CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. Phase 1
Recruiting NCT06056752 - QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Suspended NCT01974479 - Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia Phase 1
Completed NCT00289562 - Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT06034275 - Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies Phase 1
Recruiting NCT04191941 - Treatment of Hematological Malignancy With Novel CAR-T Cells. Early Phase 1
Recruiting NCT05333302 - Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma Phase 1
Recruiting NCT04129099 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Early Phase 1
Recruiting NCT05651191 - To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL Early Phase 1
Withdrawn NCT05571540 - Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL Phase 1/Phase 2
Recruiting NCT03281551 - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma Phase 1
Recruiting NCT05379647 - Natural Killer (NK) Cell Therapy for B-Cell Malignancies Phase 1
Withdrawn NCT04156659 - Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL Phase 2
Recruiting NCT04094311 - Study of Out of Specification for Tisagenlecleucel Phase 3
Completed NCT01207388 - Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 2
Active, not recruiting NCT03467256 - CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL Phase 1/Phase 2
Not yet recruiting NCT06208735 - CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies Phase 1
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Not yet recruiting NCT06326008 - Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial Phase 1